NYSE:STXS
Stereotaxis, Inc.
A robotics-enabled medical technology provider offering software-defined navigation solutions for minimally invasive surgeries.
Key Metrics
Investment Thesis
Bull Case
Stereotaxis offers exposure to the high-growth robotic surgery market with a differentiated software-defined platform that could yield superior margins as scale increases. The company's strong IP moat and recurring revenue model from software licensing provide a predictable cash flow trajectory once profitability is achieved. Early adoption of their navigation systems by leading academic centers establishes a valuable pipeline for future upselling and global expansion.
Bear Case
Investors should avoid this stock due to the persistent inability to generate positive free cash flow, evidenced by a $24 million net loss in 2024. The company's current liquidity position is fragile with only $12.2 million in cash against $35.3 million in total liabilities and no dividend history. Without a clear path to profitability or significant capital injection, the risk of dilution through share issuances remains high.
About Stereotaxis, Inc.
Stereotaxis Inc. is a medical technology company specializing in stereotactic navigation systems that enable precise robotic-assisted surgery across neurosurgery, orthopedics, and other specialties. The company serves hospitals, ambulatory surgery centers, and academic institutions globally with its proprietary software-defined robotic platforms. Key products include the STX2000 system designed to enhance surgical precision while reducing operation times and improving patient outcomes.
Analysis
Management Discussion
Despite a slight revenue stabilization to $26.9 million in 2024 compared to previous years, the company continues to burn cash with an operating loss of $24.7 million driven by elevated general and administrative costs. The net change in cash was negative $8.1 million, reducing total cash and equivalents from $20.6 million to $12.2 million over the reporting period. While R&D investments remain steady at $9.8 million, the widening gap between revenue growth and expense scaling indicates a need for significant operational efficiency improvements.
Industry Overview
The medical robotics industry is experiencing rapid expansion driven by demand for minimally invasive procedures and advanced surgical precision technologies. However, the sector is characterized by high barriers to entry, intense competition from established players like Intuitive Surgical, and significant capital requirements for R&D. Regulatory approval processes in both the US and international markets continue to create long development cycles before products can reach commercialization.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $28.1M | $26.8M | $26.9M |
| Cost of Revenue | $9.7M | $11.9M | $12.3M |
| Gross Profit | $18.5M | $14.9M | $14.6M |
| Operating Expenses | $37.2M | $36.7M | $39.3M |
| Operating Income | $-18.8M | $-21.8M | $-24.7M |
| R&D | $10.6M | $10.3M | $9.8M |
| G&A | $14.4M | $14.1M | $17.2M |
| Marketing | $12.3M | $12.4M | $12.4M |
| Stock-Based Comp | $10.6M | $10.6M | $10.3M |
| Depreciation | $429.0K | $595.0K | $587.0K |
| Amortization | — | — | $400.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-18.8M | $-21.8M | $-24.7M |
| Income Tax | $-484.0K | $-1.1M | $-694.0K |
| Continuing Ops | $-18.3M | $-20.7M | $-24.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-18.3M | $-20.7M | $-24.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-18.3M | $-20.7M | $-24.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $43.2M | $33.3M | $26.4M |
| Cash & Equivalents | $8.6M | $19.8M | $12.2M |
| Marketable Securities | $19.8M | — | — |
| Accounts Receivable | $5.1M | $3.8M | $3.8M |
| Inventory | $7.9M | $8.4M | $8.3M |
| Prepaid Expenses | $1.3M | $676.0K | $1.8M |
| Other Current Assets | $525.0K | $525.0K | $219.0K |
| Long-Term Assets | $10.2M | $8.6M | $20.3M |
| PP&E (Net) | $3.8M | $3.3M | $3.6M |
| Intangibles | — | — | $7.4M |
| Goodwill | — | — | $3.8M |
| Operating Leases | $5.4M | $5.0M | $5.5M |
| Other LT Assets | $952.0K | $356.0K | $107.0K |
| Total Assets | $53.4M | $41.9M | $46.7M |
| Current Liabilities | $14.3M | $13.2M | $21.6M |
| Accounts Payable | $3.3M | $3.2M | $5.7M |
| Current Leases | $373.0K | $428.0K | $570.0K |
| Deferred Revenue | $7.3M | $6.7M | $6.8M |
| Other Current Liab | $0 | $0 | $5.6M |
| Long-Term Liabilities | $7.2M | $6.7M | $13.7M |
| LT Operating Leases | $5.5M | $5.1M | $5.4M |
| Other LT Liab | $51.0K | $43.0K | $6.2M |
| Total Liabilities | $21.5M | $20.0M | $35.3M |
| Shareholders' Equity | $31.9M | $21.9M | $11.4M |
| Paid-In Capital | $543.4M | $554.1M | $567.9M |
| Retained Earnings | $-517.0M | $-537.7M | $-561.7M |
| Total L&E | $53.4M | $41.9M | $46.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-18.3M | $-20.7M | $-24.0M |
| Non-Cash Adjustments | $8.0M | $13.8M | $15.5M |
| Working Capital Changes | $1.9M | $-2.3M | $3.0K |
| Cash from Operations | $-8.4M | $-9.1M | $-8.5M |
| Cash from Investing | $-22.1M | $19.8M | $74.0K |
| Dividends Paid | $0 | $0 | $0 |
| Cash from Financing | $220.0K | $81.0K | $297.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-30.3M | $10.7M | $-8.1M |
| Beginning Cash | $40.1M | $9.9M | $20.6M |
| Ending Cash | $9.9M | $20.6M | $12.4M |
Frequently Asked Questions
How does Stereotaxis, Inc. make money?
Revenue is primarily derived from the sale of proprietary stereotactic navigation systems, recurring software licensing fees tied to their platform, and ongoing service and maintenance contracts. The company also generates income through international expansion efforts and partnerships with major healthcare providers in neurosurgery and orthopedics markets.
What are the main risks for STXS?
The company faces significant liquidity concerns given the $24 million net loss and substantial retained earnings deficit of over $560 million relative to current cash reserves. High operating expenses, particularly in general administration ($17.2M) and marketing ($12.4M), coupled with minimal organic revenue growth, threaten long-term solvency. Dependence on large hospital procurement cycles and potential delays in new product launches could further compress margins. Regulatory scrutiny and changes in reimbursement policies for robotic surgery procedures pose additional uncertainty.
What is STXS's competitive advantage?
Stereotaxis possesses a robust intellectual property portfolio protecting its unique robotic navigation algorithms and system architecture. The company benefits from a highly specialized engineering team capable of rapid software iteration, creating a sticky ecosystem for surgical centers. Its modular 'software-defined' hardware approach allows for faster updates and customization compared to traditional rigid robotic competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.